Cosmetic cross-reference Noindex: medium evidence

Hetaflur

CAS 3151-59-5

Hetaflur (CAS 3151-59-5) is a Phase 2 pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral / FAERS
Adverse signals
0
SOURCE IUPHAR / PharmGKB
PubMed IDs
0
SOURCE ChEMBL 36 B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Hetaflur
CAS Number
3151-59-5
UNII
S58EH61Q1Y
InChIKey
KMXTYZBQPJXGNK-UHFFFAOYSA-N
ChEMBL ID
CHEMBL2104336
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
SOURCE ChEMBL 36 B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2
Mid-stage clinical development phase from the compound identifier source.
ChEMBL CHEMBL2104336 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Hetaflur used for in pharmaceutical contexts?

Hetaflur (CAS 3151-59-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Hetaflur?

No adverse-event association or SIDER side-effect rows are rendered for Hetaflur in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Hetaflur also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Cetylamine Hydrofluoride with EU status "restricted".

What clinical phase is Hetaflur in?

Hetaflur is rendered with ChEMBL max phase 2.